


Claims

1. A compound of Formula (I), or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof,



wherein

X is selected from the group consisting of bond and $-\text{CH}_2-$;


Z^1 is selected from the group consisting of chelator and NT;

NT is selected from the group consisting of H, Ac, Hex, HPA, HO-Succinyl, SaPr, Iva, HYDAc, Bio, nBuCAyl, AF488Ahx, and Hib;

L^1 is selected from the group consisting of a bond and $-(\text{Xaa1})_k$,

k is selected from the group consisting of 1, 2, and 3,

Xaa1 is each and individually an amino acid residue, preferably the amino acid residue is selected from the group consisting of an α -amino acid residue, a β -amino acid residue, a γ -amino acid residue, a δ -amino acid residue, an ϵ -amino acid residue, an ω -amino acid residue, and an amino acid residue of Formula (YI),



g is an integer selected from the group consisting of 0-23,

wherein,


if $k = 1$, Xaa1 is covalently bound to Z^1 and covalently bound to Xaa2,

if $k = 2$, a first of the two Xaa1 is covalently bound to Z^1 and covalently bound to a second of the two Xaa1, and the second of the two Xaa1 is covalently bound to the first of the two Xaa1 and covalently bound to Xaa2,

if $k = 3$, a first of the three Xaa1 is covalently bound to Z^1 and covalently bound to a second of the three Xaa1, the second of the three Xaa1 is covalently bound to the first of the three Xaa1 and covalently bound to a third of the three Xaa1, and the third of the three Xaa1 is covalently bound to the second of the three Xaa1 and covalently bound to Xaa2;

wherein when L^1 is bond, then Z^1 is NT;

Xaa2 is selected from the group consisting of Formula (II) and Formula (III):



wherein R^{2a} is selected from the group consisting of H, (C_1-C_6) alkyl, and CH_2R^{2g} ;

R^{2g} is selected from the group consisting of OH, and CO_2H ;

R^{2b} is selected from the group consisting of H and (C_1-C_6) alkyl;

or alternatively, R^{2a} and R^{2b} can together form a 5 or 6 membered carbocycle or heterocycle,

R^{2c} is selected from the group consisting of H and CH_3 ;


R^{2d} is selected from the group consisting of H, F, and OH;

R^{2e} is selected from the group consisting of H and F;

R^{2f} is selected from the group consisting of H and CH_3 ;

with the proviso that Xaa2 can be absent when L^1 is bond and NT is Hib;

Xaa3 is selected from Formula (IV):




wherein R^{3a} is selected from the group consisting of aryl, (C₅-C₆)heteroaryl, indol-3-yl, 6-chloro-1H-indol-3-yl, and -S-CH₂-phenyl; and wherein said aryl or said heteroaryl ring of R^{3a} is optionally substituted by 1, 2, or 3 substituents independently selected from the group consisting of halogen, (C₁-C₆)alkyl, CN, OH, and -O(C₁-C₃)alkyl, wherein said (C₁-C₆)alkyl may optionally be substituted by one or more fluorine;

R^{3b} is selected from the group consisting of H and CH₃;

h is selected from the group consisting of 1 and 2;

Xaa5 is selected from the group consisting of Formula (Va), Formula (Vb), Hgn, lys, Nle, Tap, Aph, and Gln:



wherein R^{5a} is selected from the group consisting of H, (C₁-C₆)alkyl, Ac, C(=NR^{5d})NR^{5e}R^{5f}, and Bio;

R^{5d} is selected from the group consisting of H and CH₃;

R^{5e} and R^{5f} are independently selected from the group consisting of H and (C₁-C₆)alkyl;


R^{5b} is selected from the group consisting of H and (C₁-C₆)alkyl;

R^{5c} is selected from the group consisting of H and CH₃;

m is selected from the group consisting of 2, 3, 4, and 5; and

R^{5g} , R^{5h} , and R^{5i} are independently selected from the group consisting of (C₁-C₆)alkyl;

Xaa6 is selected from the group consisting of Formula (VI), Formula (VII), Nle, and arg:



wherein R^{6a} is selected from the group consisting of H, $C(=NR^{6e})NR^{6f}R^{6g}$, $C(=O)R^{6h}$, and pyridyl;

R^{6e} is selected from the group consisting of H and CH_3 ;

R^{6f} is selected from the group consisting of H, (C_1-C_6) alkyl, Ac, NO_2 , and $C(=O)NR^{6i}R^{6j}$;

R^{6i} and R^{6j} are independently selected from the group consisting of H and (C_1-C_2) alkyl;

R^{6g} is selected from the group consisting of H and (C_1-C_6) alkyl;

or alternatively, R^{6e} and R^{6f} can together form a 5 or 6 membered heterocycle;

R^{6h} is selected from the group consisting of (C_1-C_6) alkyl, $NR^{6k}R^{6m}$, and $NR^{6n}C(=NR^{6p})NR^{6q}R^{6r}$;

R^{6k} and R^{6m} are independently selected from the group consisting of H and (C_1-C_6) alkyl;

R^{6n} and R^{6p} are independently selected from the group consisting of H and CH_3 ;

R^{6q} and R^{6r} are independently selected from the group consisting of H and (C_1-C_6) alkyl;

R^{6b} is selected from the group consisting of H and (C_1-C_6) alkyl;

R^{6c} is selected from the group consisting of H and CH_3 ;

n is selected from the group consisting of 1, 2, 3, and 4;


R^{6d} is selected from the group consisting of $NR^{6s}C(=NR^{6t})NR^{6u}R^{6v}$, OH, and $NR^{6w}R^{6x}$;

R^{6s} and R^{6t} are independently selected from the group consisting of H and CH_3 ;

R^{6u} , R^{6v} , R^{6w} , and R^{6x} are independently selected from the group consisting of H and (C_1-C_6) alkyl; and

q is selected from the group consisting of 2, 3, and 4;

Xaa7 is an amino acid residue, wherein the amino acid residue is preferably selected from the group consisting of Formula (VIII), Formula (IX), Formula (X), Formula (XI), Dtc, and Oic:



wherein R^{7a} is selected from the group consisting of H, (C₁-C₆)alkyl, and (CH₂)_tR^{7g};

R^{7g} is selected from the group consisting of OH, CO₂H, and NR^{7h}R⁷ⁱ;

R^{7h} and R⁷ⁱ are independently selected from the group consisting of H and (C₁-C₆)alkyl;

t is selected from the group consisting of 1, 2, 3 and 4;

R^{7b} is selected from the group consisting of H and (C₁-C₆)alkyl;

or alternatively, R^{7a} and R^{7b} can together form a 5 or 6 membered carbocycle or heterocycle,

R^{7c} is selected from the group consisting of H and CH₃;

R^{7d} is selected from the group consisting of H, F, and OH;

R^{7e} is selected from the group consisting of H and F;

R^{7f} is selected from the group consisting of H and CH₃;

u is selected from the group consisting of 2, 3, and 4;

L³ is selected from the group consisting of bond and -(Xab1)_v-,

wherein v is selected from the group consisting of 1, 2, and 3,

Xab1 is each and individually an amino acid residue, preferably the amino acid residue is selected from the group consisting of an α-amino acid residue, a β amino acid residue, a γ-amino acid residue, a δ-amino acid residue, an ε-amino acid residue, an ω-amino acid residue, and an amino acid residue of Formula (YI),

if v = 1, Xab1 is covalently bound to Z³ and covalently bound to a side chain amino function of Formula (X) or of Formula (XI),


if $v = 2$, a first of the two Xab1 is covalently bound to Z^3 and covalently bound to a second of the two Xab1, and the second of the two Xab1 is covalently bound to the first of the two Xab1 and covalently bound to a side chain amino function of Formula (X) or of Formula (XI),

if $v = 3$, a first of the three Xab1 is covalently bound to Z^3 and covalently bound to a second of the three Xab1, the second of the three Xab1 is covalently bound to the first of the three Xab1 and covalently bound to a third of the three Xab1, and the third of the three Xab1 is covalently bound to the second of the three Xab1 and covalently bound to a side chain amino function of Formula (X) or of Formula (XI);

Z^3 is selected from the group consisting of H and chelator;

Xaa8 is an α -amino acid residue, wherein the α -nitrogen atom of Xaa8 is unsubstituted or is optionally substituted by CH_3 ;

Xaa10 is Formula (XII):



wherein:

R^{10a} is selected from the group consisting of $(\text{C}_1\text{-C}_6)\text{alkyl}$;

R^{10b} is selected from the group consisting of H and $(\text{C}_1\text{-C}_6)\text{alkyl}$;

or alternatively, R^{10a} and R^{10b} can together form a 5 or 6 membered carbocycle or heterocycle,

R^{10c} is selected from the group consisting of H and CH_3 ;

L^2 is selected from the group consisting of:

bond and $-\text{Xaa11}-(\text{Xaa12})_s-$, such that Xaa11 is covalently bound to Xaa10;

Xaa11 is an amino acid residue, wherein the amino acid residue is preferably selected from the group consisting of an α -amino acid residue, a β -amino acid residue, a γ -amino acid residue, a δ -amino acid residue, an ϵ -amino acid residue, an ω -amino acid residue, and an amino acid residue of Formula (YI);

s is selected from the group consisting of 0, 1, 2, 3, 4, and 5; and

Xaa12 is each and individually an amino acid residue, wherein the amino acid residue is preferably selected from the group comprising an α -amino acid residue, a β -amino acid residue, a γ -amino acid residue, a δ -amino acid residue, an ε -amino acid residue, an ω -amino acid residue, and an amino acid residue of Formula (YI),

if $s = 0$, Xaa11 is covalently bound to Z^2 ,

if $s = 1$, Xaa12 is covalently bound to Xaa11 and covalently bound to Z^2 ,


if $s = 2$, a first of the two Xaa12 is covalently bound to Xaa11 and covalently bound to a second of the two Xaa12, and the second of the two Xaa12 is covalently bound to the first of the two Xaa12 and covalently bound to Z^2 ,

if $s = 3$, a first of the three Xaa12 is covalently bound to Xaa11 and covalently bound to a second of the three Xaa12, the second of the three Xaa12 is covalently bound to the first of the three Xaa12 and covalently bound to a third of the three Xaa12, and the third of the three Xaa12 is covalently bound to the second of the three Xaa12 and covalently bound to Z^2 ,


if $s = 4$, a first of the four Xaa12 is covalently bound to Xaa11 and covalently bound to a second of the four Xaa12, the second of the four Xaa12 is covalently bound to the first of the four Xaa12 and covalently bound to a third of the four Xaa12, the third of the four Xaa12 is covalently bound to the second of the four Xaa12 and covalently bound to a fourth of the four Xaa12, and the fourth of the four Xaa12 is covalently bound to the third of the four Xaa12 and covalently bound to Z^2 ,

if $s = 5$, a first of the five Xaa12 is covalently bound to Xaa11 and covalently bound to a second of the five Xaa12, the second of the five Xaa12 is covalently bound to the first of the five Xaa12 and covalently bound to a third of the five Xaa12, the third of the five Xaa12 is covalently bound to the second of the five Xaa12 and covalently bound to a fourth of the five Xaa12, the fourth of the five Xaa12 is covalently bound to the third of the five Xaa12 and covalently bound to a fifth of the five Xaa12, and the fifth of the five Xaa12 is covalently bound to the fourth of the five Xaa12 and covalently bound to Z^2 ;

Z^2 is selected from the group consisting of CT, XDa-chelator and an α -amino acid residue of Formula (CT-I):



CT is selected from the group consisting of Formula (CT-II), Formula (CT-III), AF488N3K-NH₂, OH, and Thiol-OH:



wherein:

R^{CT1} is selected from the group consisting of H and CH₃;

R^{CT2} is selected from the group consisting of H and (C₁-C₆)alkyl;

R^{CT3} and R^{CT4} are each and individually selected from the group consisting of H and CH₃;

R^{CT5} is selected from the group consisting of H and (C₁-C₆)alkyl;

x is selected from the group consisting of 2-10;

XDa is a diamine, wherein said diamine is preferably selected from the group consisting of en and Ape;

w is selected from the group consisting of 1, 2, 3, 4, 5, and 6;

L⁴ is selected from the group consisting of a bond and -(Xac1)_y-,

wherein:

y is selected from the group consisting of 0, 1, 2, and 3,

Xac1 is each and individually an amino acid residue, preferably the amino acid residue is selected from the group comprising an α-amino acid residue, a β-amino acid residue, a γ-amino acid residue, a δ-amino acid residue, an ε-amino acid residue, an ω-amino acid residue and an amino acid residue of Formula (YI),

if y = 0, the side chain amino function of the α-amino acid residue of Formula (CT-I) is covalently bound to Z⁴,

if y = 1, Xac1 is covalently bound to the side chain amino function of the α-amino acid residue of Formula (CT-I) and covalently bound to Z⁴,

if y = 2, a first of the two Xac1 is covalently bound to the side chain amino function of the α-amino acid residue of Formula (CT-I) and covalently bound to a second of the two Xac1, and the second of the two Xac1 is covalently bound to the first of the two Xac1 and covalently bound to Z⁴,

if $y = 3$, a first of the three Xac1 is covalently bound to the side chain amino function of the α -amino acid residue of Formula (CT-I) and covalently bound to a second of the three Xac1, the second of the three Xac1 is covalently bound to the first of the three Xac1 and covalently bound to a third of the three Xac1, and the third of the three Xac1 is covalently bound to the second of the three Xac1 and covalently bound to Z^4 ,


if $y = 4$, a first of the four Xac1 is covalently bound to the side chain amino function of the α -amino acid residue of Formula (CT-I) and covalently bound to a second of the four Xac1, the second of the four Xac1 is covalently bound to the first of the four Xac1 and covalently bound to a third of the four Xac1, the third of the four Xac1 is covalently bound to the second of the four Xac1 and covalently bound to a fourth of the four Xac1, and the fourth of the four Xac1 is covalently bound to the third of the four Xac1 and covalently bound to Z^4 ;

Z^4 is selected from the group consisting of H and chelator;

with the proviso that if L^2 is bond and CT is Formula (CT-II) wherein R^{CT1} is selected from the group consisting of H and CH_3 and R^{CT2} is (C_4-C_6) alkyl, then Xaa10 can be absent;

and wherein the compound of Formula (I) may optionally comprise a therapeutically active nuclide or a diagnostically active nuclide.

2. A compound of Formula (I), or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof,



wherein

X is selected from the group consisting of bond and $-\text{CH}_2-$;

Z^1 is selected from the group consisting of chelator and NT;

NT is selected from the group consisting of H, Ac, Hex, HPA, HO-Succinyl, SaPr, Iva, HYDAc, Bio, nBuCAyl, AF488Ahx, and Hib;

L^1 is selected from the group consisting of bond and $-(\text{Xaa1})_k-$;

k is selected from the group consisting of 1, 2, and 3;

wherein,

if $k = 1$, Xaa1 is covalently bound to Z^1 and covalently bound to Xaa2,

if $k = 2$, a first of the two Xaa1 is covalently bound to Z^1 and covalently bound to a second of the two Xaa1, and the second of the two Xaa1 is covalently bound to the first of the two Xaa1 and covalently bound to Xaa2,

if $k = 3$, a first of the three Xaa1 is covalently bound to Z^1 and covalently bound to a second of the three Xaa1, the second of the three Xaa1 is covalently bound to the first of the three Xaa1 and covalently bound to a third of the three Xaa1, and the third of the three Xaa1 is covalently bound to the second of the three Xaa1 and covalently bound to Xaa2;


wherein when L^1 is bond, then Z^1 is NT;

Xaa1 is each and individually selected from the group consisting of Thr, Ala, Ser, Pamp, Leu, Ile, Nmt, Pamb, Ahx, APAc, PPAc, Bal, Cmp, Pab, O2Oc, Met, and Ttds;

Xaa2 is selected from the group consisting of Aib, Ala, Amd, Ams, amd, ams, Deg, Nmg, Pam, and Pro; with the proviso that Xaa2 can be absent when L^1 is bond and NT is Hib;

Xaa3 is selected from the group consisting of Phe, Nmf, 1Ni, 2Ni, 6Clw, Cys(Bzl), Hfe, Trp, Mpa, Opa, and Ppa, wherein Phe, Nmf, and Hfe are optionally substituted by 1 or 2 substituents independently selected from the group consisting of halogen, CH_3 , CN, CF_3 , and OH;

Xaa5 is selected from the group consisting of Formula (Va), Formula (Vb), Hgn, lys, Nle, Tap, Aph, and Gln:



wherein R^{5a} is selected from the group consisting of H, (C₁-C₆)alkyl, Ac, C(=NR^{5d})NR^{5e}R^{5f}, and Bio;

R^{5d} is selected from the group consisting of H and CH₃;

R^{5e} and R^{5f} are independently selected from the group consisting of H and (C₁-C₆)alkyl;


R^{5b} is selected from the group consisting of H and (C₁-C₆)alkyl;

R^{5c} is selected from the group consisting of H and CH₃;

m is selected from the group consisting of 2, 3, 4, and 5; and

R^{5g} , R^{5h} , and R^{5i} are independently selected from the group consisting of (C₁-C₆)alkyl;

Xaa6 is selected from the group consisting of Formula (VI), Formula (VII), Nle, and arg:



wherein R^{6a} is selected from the group consisting of H, C(=NR^{6e})NR^{6f}R^{6g}, C(=O)R^{6h}, and pyridyl;

R^{6e} is selected from the group consisting of H and CH₃;

R^{6f} is selected from the group consisting of H, (C₁-C₆)alkyl, Ac, NO₂, and C(=O)NR⁶ⁱR^{6j};

R^{6i} and R^{6j} are independently selected from the group consisting of H and (C₁-C₂)alkyl;

R^{6g} is selected from the group consisting of H and (C₁-C₆)alkyl;

or alternatively, R^{6e} and R^{6f} can together form a 5 or 6 membered heterocycle;

R^{6h} is selected from the group consisting of (C₁-C₆)alkyl, NR^{6k}R^{6m}, and NR⁶ⁿC(=NR^{6p})NR^{6q}R^{6r};

R^{6k} and R^{6m} are independently selected from the group consisting of H and (C₁-C₆)alkyl;

R^{6n} and R^{6p} are independently selected from the group consisting of H and CH₃;

R^{6q} and R^{6r} are independently selected from the group consisting of H and (C₁-C₆)alkyl;

R^{6b} is selected from the group consisting of H and (C₁-C₆)alkyl;

R^{6c} is selected from the group consisting of H and CH₃;

n is selected from the group consisting of 1, 2, 3, and 4;


R^{6d} is selected from the group consisting of $NR^{6s}C(=NR^{6t})NR^{6u}R^{6v}$, OH, and $NR^{6w}R^{6x}$;

R^{6s} and R^{6t} are independently selected from the group consisting of H and CH₃;

R^{6u} , R^{6v} , R^{6w} , and R^{6x} are independently selected from the group consisting of H and (C₁-C₆)alkyl; and

q is selected from the group consisting of 2, 3, and 4;

Xaa7 is selected from the group consisting of Formula (VIII), Formula (IX), Formula (X), Formula (XI), Dtc, and Oic:



wherein R^{7a} is selected from the group consisting of H, (C₁-C₆)alkyl, and (CH₂)_tR^{7g};

R^{7g} is selected from the group consisting of OH, CO₂H, and $NR^{7h}R^{7i}$;

R^{7h} and R^{7i} are independently selected from the group consisting of H and (C₁-C₆)alkyl;

t is selected from the group consisting of 1, 2, 3 and 4;

R^{7b} is selected from the group consisting of H and (C₁-C₆)alkyl;

or alternatively, R^{7a} and R^{7b} can together form a 5 or 6 membered carbocycle or heterocycle,

R^{7c} is selected from the group consisting of H and CH₃;

R^{7d} is selected from the group consisting of H, F, and OH;

R^{7e} is selected from the group consisting of H and F;

R^{7f} is selected from the group consisting of H and CH_3 ;

u is selected from the group consisting of 2, 3, and 4;

L^3 is selected from the group consisting of bond and $-(Xab1)_v-$;

v is selected from the group consisting of 1, 2, and 3;

Xab1 is each and individually selected from the group consisting of Ttds, Pamb, APAc, O2Oc, Ahx, Pab, and Cmp;

wherein, if $v = 1$, Xab1 is covalently bound to Z^3 and covalently bound to a side chain amino function of Formula (X) or of Formula (XI),


if $v = 2$, a first of the two Xab1 is covalently bound to Z^3 and covalently bound to a second of the two Xab1, and the second of the two Xab1 is covalently bound to the first of the two Xab1 and covalently bound to a side chain amino function of Formula (X) or of Formula (XI),

if $v = 3$, a first of the three Xab1 is covalently bound to Z^3 and covalently bound to a second of the three Xab1, the second of the three Xab1 is covalently bound to the first of the three Xab1 and covalently bound to a third of the three Xab1, and the third of the three Xab1 is covalently bound to the second of the three Xab1 and covalently bound to a side chain amino function of Formula (X) or of Formula (XI);

Z^3 is selected from the group consisting of H and chelator;

Xaa8 is an α -amino acid residue, wherein the α -nitrogen atom of Xaa8 is unsubstituted or is optionally substituted by CH_3 ;

Xaa10 is Formula (XII)



wherein

R^{10a} is selected from the group consisting of (C_1-C_6) alkyl;

R^{10b} is selected from the group consisting of H and CH_3 ;

R^{10c} is selected from the group consisting of H and CH_3 ;

L^2 is selected from the group consisting of

bond and $-Xaa11-(Xaa12)_s-$, such that Xaa11 is covalently bound to Xaa10;

Xaa11 is selected from the group consisting of Thr, Ala, Bal, Gab, Gln, Glu, Gly, Leu, Nmt, Phe, Pro, and Trp;

s is selected from the group consisting of 0, 1, 2, 3, 4, and 5; and

Xaa12 is each and individually selected from the group consisting of Asp, asp, Ala, Gab, Ttds, Pamb, Cmp, O2Oc, APAc, Gly, Ser, Lys(Bio), and Pab;

wherein, if $s = 0$, Xaa11 is covalently bound to Z^2 ,

if $s = 1$, Xaa12 is covalently bound to Xaa11 and covalently bound to Z^2 ,


if $s = 2$, a first of the two Xaa12 is covalently bound to Xaa11 and covalently bound to a second of the two Xaa12, and the second of the two Xaa12 is covalently bound to the first of the two Xaa12 and covalently bound to Z^2 ,

if $s = 3$, a first of the three Xaa12 is covalently bound to Xaa11 and covalently bound to a second of the three Xaa12, the second of the three Xaa12 is covalently bound to the first of the three Xaa12 and covalently bound to a third of the three Xaa12, and the third of the three Xaa12 is covalently bound to the second of the three Xaa12 and covalently bound to Z^2 ,

if $s = 4$, a first of the four Xaa12 is covalently bound to Xaa11 and covalently bound to a second of the four Xaa12, the second of the four Xaa12 is covalently bound to the first of the four Xaa12 and covalently bound to a third of the four Xaa12, the third of the four Xaa12 is covalently bound to the second of the four Xaa12 and covalently bound to a fourth of the four Xaa12, and the fourth of the four Xaa12 is covalently bound to the third of the four Xaa12 and covalently bound to Z^2 ,

if $s = 5$, a first of the five Xaa12 is covalently bound to Xaa11 and covalently bound to a second of the five Xaa12, the second of the five Xaa12 is covalently bound to the first of the five Xaa12 and covalently bound to a third of the five Xaa12, the third of the five Xaa12 is covalently bound to the second of the five Xaa12 and covalently bound to a fourth of the five Xaa12, the fourth of the five Xaa12 is covalently bound to the third of the five Xaa12 and covalently bound to a fifth of the five Xaa12, and the fifth of the five Xaa12 is covalently bound to the fourth of the five Xaa12 and covalently bound to Z^2 ;

Z^2 is selected from the group consisting of CT, -en-chelator, -Ape-chelator, and Formula (CT-I)



CT is selected from the group consisting of NH₂, en, en(Me)₂, en(Me), NHBu, NHnPen, AF488N3K-NH₂, OH, and Throl-OH;

w is selected from the group consisting of 2, 3, and 4;

L⁴ is selected from the group consisting of a bond, Ttds, Pamb, APAc, O2Oc, Ahx, Pab, and Cmp;

Z⁴ is chelator;

with the proviso that Xaa10 can be absent if L² is bond and CT is NHnPen;

and wherein the compound of Formula (I) may optionally comprise a therapeutically active nuclide or a diagnostically active nuclide.

3. The compound of any one of claims 1 and 2, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof, wherein only 1 of Z¹, Z², Z³, and Z⁴ comprises a chelator.


4. The compound of any one of claims 1, 2 and 3, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof, wherein

Z² is CT; and

Xaa7 is selected from the group consisting of Formula (VIII), Formula (IX), Dtc, and Oic, preferably wherein Z¹ is chelator.

5. The compound of claim 4, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof, wherein L¹ is -(Xaa1)_k-; and wherein k is selected from the group consisting of 1 and 2.

6. The compound of any one of claims 4 and 5, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof, wherein k is 2, and L¹ is Formula (XIII):



wherein Xaa1^a is covalently bound to Xaa2;

Xaa1^a is selected from the group consisting of Thr, Ile, and Leu; and

Xaa1^b is selected from the group consisting of Cmp, Ttds, Pamb, Ahx, APAc, Bal, O2Oc, and Pab.

7. The compound of any one of claims 4 to 6, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof, wherein k is 1, and Xaa1 is selected from the group consisting of Pamb, Bal, Cmp, Pab, Ahx, APAc, Thr, Pamp, and PPAc.

8. The compound of any one of claims 4 to 7, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof, wherein L² is selected from the group consisting of bond and -Xaa11-(Xaa12)_s-; and s is selected from the group consisting of 0 and 1, wherein preferably

(a) L² is -Xaa11-(Xaa12)_s-;

s is selected from the group consisting of 0 and 1; and

Xaa11 is selected from the group consisting of Thr, Bal, Gln, Phe, Gab, Nmt, Gly, Leu, Trp, Glu, and Pro, more preferably s is 0,

(b) s is 1; Xaa12 is Asp and, preferably, Xaa11 is selected from the group consisting of Thr, Bal, Gln, Phe, Gab, Nmt, Gly, Leu, Trp, Glu, and Pro, or

(c) L² is bond.

9. The compound of claim 8, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof, wherein CT is selected from the group consisting of NH₂, en, en(Me), en(Me)₂, NHBu, Throl-OH, and OH.

10. The compound of any one of claims 4 to 8, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof, wherein L²-Z² is selected from the group consisting of Thr-NH₂, Bal-NH₂, Glu-NH₂, Pro-NH₂, Gln-NH₂, Trp-NH₂, Leu-NH₂, Gly-NH₂ and Nmt-NH₂.

11. The compound of any one of claims 4 to 10, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof, wherein Xaa7 is selected from the group consisting of Formula (VIII), Formula (IX), Dtc, and Oic, wherein

R^{7a} is selected from the group consisting of H, (C₁-C₆)alkyl, and (CH₂)_tR^{7g};

t is selected from the group consisting of 1 and 2; and

R^{7g} is selected from the group consisting of OH, CO₂H, and NH₂,

preferably Xaa7 is selected from the group consisting of Aib, Ala, Glu, Pro, Dfp, glu, Amd, 4Tfp, Pam, Deg, Nmg, Ams, ams, amd, Dtc, and Oic, or

preferably Xaa7 is selected from Formula (VIII), and wherein

R^{7a} is selected from the group consisting of H, (C₁-C₂)alkyl, CH₂OH, CH₂CO₂H, and CH₂CH₂CO₂H;

R^{7b} is selected from the group consisting of H and (C₁-C₂)alkyl; and

R^{7c} is H; more preferably wherein Xaa7 is selected from the group consisting of Aib and Ala.

12. The compound, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof, of any one of claims 1, 2 and 3, wherein

Z^1 is NT, and

Xaa7 is selected from the group consisting of Formula (VIII), Formula (IX), Dtc, and Oic,


preferably Z^2 is selected from the group consisting of en-chelator, -Ape-chelator, and Formula (CT-I), wherein if Z^2 is Formula (CT-I), then Z^4 is chelator.

13. The compound of claim 12, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof, wherein

L^1 is selected from the group consisting of bond and (Xaa1)_k; and

k is selected from the group consisting of 1 and 2.

preferably k is 2 and L^1 is Formula (XIII)



wherein Xaa1^a is covalently bound to Xaa2 of Formula (I);

Xaa1^a is Thr; and

Xaa1^b is Met or Cmp,

more preferably Xaa1^b is Met,

14. The compound of claim 13, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof, wherein NT is selected from the group consisting of H, Ac, and nBuCAyl.

15. The compound of claim 13, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof, wherein

(a) k is 1, and Xaa1 is selected from the group consisting of Thr, Ala, Pamp, and Ser,

preferably Xaa1 is selected from the group consisting of Thr and Pamp; and NT is selected from the group consisting of Ac, nBuCAyl, and Hex, or

(b) L¹ is bond, preferably NT is selected from the group consisting of Ac, HPA, HYDAc, Iva, SaPr, and HO-Succinyl.

16. The compound of any one of claims 12 to 15, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof, wherein

L² is -Xaa11-(Xaa12)_s; and

s is selected from the group consisting of 0, 1, and 2,

preferably Z² is Formula (CT-I),

17. The compound of claim 16, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof, wherein Xaa11 is Thr.

18. The compound of any one of claims 16 and 17, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof, wherein L² is

a)

-Xaa11-(Xaa12)_s; s is 1; and

Xaa12 is selected from the group consisting of Asp, Cmp, Ttds, Pamb, O2Oc, APAc, and Pab,

or

b)

-Xaa11-(Xaa12)_s; and s is 2; and L² has the structure

-Xaa11-Xaa12^a-Xaa12^b-; wherein

Xaa12^a is selected from the group consisting of Asp, Cmp, Ttds, Pamb, O2Oc, APAc, and Pab; and

Xaa12^b is Ttds.

19. The compound of any one of claims 12 to 16, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof, wherein Z² is selected from the group consisting of -en-chelator and -Ape-chelator, preferably L² is a bond or Xaa11, wherein if L² is Xaa11, Xaa11 is preferably Thr.

20. The compound of any one of claims 12 to 19, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof, wherein Xaa7 is selected from Formula (VIII), Formula (IX), Dtc, and Oic, wherein

R^{7a} is selected from the group consisting of H, (C₁-C₆) alkyl, and (CH₂)_tR^{7g};

R^{7g} is selected from the group consisting of OH and CO₂H;

t is selected from the group consisting of 1 and 2; and

R^{7b} is selected from the group consisting of H and (C₁-C₆) alkyl;

preferably Xaa7 is

a)

selected from the group consisting of Aib, Ala, Glu, Pro, Dfp, glu, Amd, 4Tfp, Pam, Deg, Nmg, Ams, ams, amd, Dtc, and Oic;

or

b)

of Formula (VIII), and wherein

R^{7a} is selected from the group consisting of H, (C₁-C₂)alkyl, CH₂OH, CH₂CO₂H, and CH₂CH₂CO₂H;

R^{7b} is selected from the group consisting of H and (C₁-C₂)alkyl; and

R^{7c} is H,

preferably Xaa7 is selected from the group consisting of Ala and Aib.

21. The compound, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof, of any one of claims 1, 2 and 3, wherein Xaa7 is selected from the group consisting of Formula (X) and Formula (XI);

Z^3 is chelator;

Z^1 is NT; and

Z^2 is CT,

preferably L^1 is selected from the group consisting of bond and -(Xaa1)_k-; and k is 1, wherein if L^1 is Xaa1, Xaa1 is preferably Thr,

more preferably NT is selected from the group consisting of Ac, SaPr, Iva, and HPA.

22. The compound of claim 21, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof, wherein L^2 is selected from the group consisting of bond and -Xaa11-(Xaa12)_s-, wherein s is selected from the group consisting of 0 and 1; preferably Xaa11 is selected from the group consisting of Thr, Gln, Phe, Gab, Nmt, Bal, Gly, Leu, Trp, Glu, and Pro, preferably CT is NH₂.

23. The compound of any one of claims 21 to 22, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof, wherein Xaa7 is selected from the group consisting of Lys and Apc, wherein to the ε-nitrogen atom of Lys or the γ-nitrogen atom of Apc a chelator is attached, wherein an optional linker is interspersed between Apc or Lys and the chelator.

24. The compound of any one of claims 21 to 23, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof, wherein Xaa7 is selected from the group consisting of Apc(DOTA), Lys(DOTAGA-O2Oc), Lys(DOTA-O2Oc), Lys(DOTA-Pab), Lys(DOTA-Ahx), Lys(DOTA-APAc), Lys(DOTA-Pamb), Lys(DOTA-Cmp), Lys(DOTA-Ttds), Lys(DOTA).

25. The compound of any one of claims 21 or 22, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof, wherein Xaa7 is selected from Formula (X), wherein

u is 4;

L^3 is $-(Xab1)_v-$;

v is 1; and

Xab1 is selected from the group consisting of Ttds, Pamb, APAc, O2Oc, Ahx, and Pab.

26. The compound of any one of claims 1 to 25, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof, wherein chelator is selected from the group consisting of DOTA, DOTAGA, LSC, NOPO, PCTA, DOTAM, Macropa, Crown, NOTA, and NODAGA.

27. The compound of any one of claims 1 to 26, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof, wherein

Xaa2 is selected from the group consisting of Aib, Ala, Ams, ams, Deg, Pam, and Pro,

Xaa3 is selected from the group consisting of Phe, 1Ni, 2Ni, 6Clw, Cys(Bzl), Hfe, and Trp, wherein Phe, Nmf, and Hfe are optionally substituted by 1 or 2 substituents independently selected from the group consisting of Cl, CH₃, F, CN, CF₃, and OH; preferably Xaa3 is selected from the group consisting of Phe and Pcf,

Xaa5 is selected from the group consisting of Formula (Va), Formula (Vb), Hgn, and Nle, and R^{5g}, R^{5h}, and R⁵ⁱ are CH₃;

preferably Xaa5 is selected from Formula (Va), and

R^{5a} is selected from the group consisting of H, CH₃, Ac, and C(=NR^{5d})NR^{5e}R^{5f};

R^{5e} and R^{5f} are independently selected from the group consisting of H and CH₃;

R^{5b} is H;

R^{5c} is H; and

m is selected from the group consisting of 3 and 4;

more preferably Xaa5 is selected from the group consisting of Lys, Lys(Me), Kip and KMe3,

Xaa6 is selected from the group consisting of Formula (VI), Formula (VII), and Nle,

wherein R^{6a} is selected from the group consisting of H, $C(=NR^{6e})NR^{6f}R^{6g}$, and $C(=O)R^{6h}$;

R^{6e} is H;

R^{6f} is selected from the group consisting of H, CH_3 , Ac, NO_2 , and $C(=O)NR^{6i}R^{6j}$;

R^{6g} is selected from the group consisting of H and CH_3 ;

R^{6h} is selected from the group consisting of CH_3 , NH_2 , and $NHC(=NH)NH_2$;

R^{6b} is H;

R^{6c} is H; and

R^{6d} is selected from the group consisting of $NHC(=NH)NH_2$ and NH_2 ;

preferably Xaa6 is

a) selected from the group consisting of Arg, Arg(Me), Cit, Egd, RMe2a, RMe3, Nle, Gln, Lys(Ac), Hgn, Arg(EtCayl), Urr, Arg(Ac), Gln(Gu), Orn, Har, RMe2, and Eew;


or

b) is of Formula (VI), and wherein

n is 3;

R^{6a} is $C(=NH)NHR^{6f}$; and

R^{6f} is selected from the group consisting of H, Ac, NO_2 , and CH_3 , more preferably Xaa6 is selected from the group consisting of Arg, Arg(Me), Cit, Egd, RMe2a and RMe3, Xaa8 is selected from the group consisting of Formula (XIV), Gly, Val, Met, Ile and Thr:



wherein R^{8a} , is selected from the group consisting of H, OH, NH_2 , $COOH$, $C(=O)NH_2$, $NHC(=NH)NH_2$, $(C_1-C_8)alkyl$, aryl, and heteroaryl;

w is selected from the group consisting of 1, 2, and 3; and


R^{8b} is selected from the group consisting of H and CH_3 ;

preferably R^{8a} is selected from the group consisting of OH, $COOH$, $C(=O)NH_2$, phenyl, $CH_2NHC(=NH)NH_2$, indole, and $CH(CH_3)_2$; and

w is selected from the group consisting of 1 and 2,

preferably Xaa8 is selected from the group consisting of Asn, Trp, Phe, Arg, Ser, Gly, Leu, Asp, Nmn, Glu, and asn, and/or

Xaa10 is Formula (XII):




; wherein

R^{10b} is selected from the group consisting of H and CH_3 ;

R^{10c} is H;


preferably Xaa10 is selected from the group consisting of Tle, Leu, Val, Npg, and Ile.

28. The compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof, wherein the compound is a compound of Formula (Ia).



(Ia)


preferably $Xaa3$ is selected from the group consisting of Phe, 1Ni, 2Ni, 6Clw, Cys(Bzl), Hfe, and Trp, wherein Phe, Nmf, and Hfe are optionally substituted by 1 or 2 substituents independently selected from the group consisting of Cl, CH_3 , F, CN, CF_3 , and OH; preferably $Xaa3$ is selected from the group consisting of Phe and Pcf, even more preferably $Xaa10$ is Formula (XII), wherein



R^{10b} is selected from the group consisting of H and CH_3 ;


R^{10c} is H;

preferably $Xaa10$ is selected from the group consisting of a compound of Formula (XIV)



more preferably R^{10a} is selected from the group consisting of $C(CH_3)_3$, $CH_2CH(CH_3)_2$, $CH(CH_3)_2$, $CH(CH_3)C_2H_5$ and $CH_2C(CH_3)_3$,

29. The compound of claim 28, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof, wherein the compound is a compound of Formula (Ib)



(Ib)

wherein R^{3c} is selected from the group consisting of H, Cl, CH_3 , F, CN, CF_3 , and OH; and R^{3c} is at the meta or para position of the phenyl ring of Formula (Ib).

30. The compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate or a hydrate thereof, wherein

Xaa2 is Aib or Ala;

Xaa3 is Phe or Pcf;

Xaa5 is Lys(Me), Lys, Kip or KMe3;

Xaa6 is Arg(Me), Arg, Egd, Cit, RMe2a or RMe3;

Xaa7 is Aib or Ala;

Xaa8 is Asn; and

Xaa10 is Tle or Leu.

31. The compound of any one of claims 12 to 20, or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein

Xaa2 is Aib or Ala;

Xaa3 is Phe or Pcf;

Xaa5 is Lys or Lys(Me);

Xaa6 is Arg or Arg(Me);

Xaa7 is Aib or Ala;

Xaa8 is Ans; and

Xaa10 is Tle or Leu.

32. The compound of claim 1, or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein the compound is selected from the following

DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys(Me)-Arg(Me)-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0194);

DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-NH₂ (PSM-0433);

DOTA-Cmp-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0492);

Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0178);

Ac-Thr-Aib-Pcf-[Cys-Lys-Cit-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0179);

Ac-Thr-Aib-Phe-[Cys-Lys-Gln-Ala-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0180);

Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Hyp-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0181);

Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Asp-Ttds-Ttds-AF488N3K-NH₂ (PSM-0183);

DOTA-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-NH₂ (PSM-0184);

Ac-Pamp-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-en-DOTA (PSM-0186);
 Ac-Thr-Deg-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0187);
 SaPr-Aib-Pcf-[Cys-Lys-Arg-Lys(DOTA-APAc)-Asn-Cys]-Tle-Thr-NH₂ (PSM-0188);
 Ac-Thr-Aib-Pcf-[Cys-Lys-Gln(Gu)-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0189);
 Ac-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-lys(DOTA-Cmp)-NH₂ (PSM-0190);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-APAc-lys(DOTA)-NH₂ (PSM-0191);
 DOTA-Ttds-Thr-Aib-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0193);
 Ac-Thr-Ala-Phe-[Cys-Lys-Arg-Glu-Asn-Cys]-Nle-Thr-Asp-NH₂ (PSM-0197);
 DOTA-Cmp-Tle-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0198);
 DOTA-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-en (PSM-0199);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys(Me)-Arg-Aib-Asn-Cys]-Tle-NH₂ (PSM-0200);
 DOTA-Pamb-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0202);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-KMe₂-Arg(Me)-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0203);
 nBuCAyl-Thr-Aib-Pcf-[Cys-Lys-Cit-Aib-Asn-Cys]-Tle-Thr-Cmp-lys(DOTA)-NH₂ (PSM-0204);
 Ac-Thr-Aib-Pcf-[Cys-Nle-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0205);
 nBuCAyl-Thr-Aib-Mcf-[Cys-Lys-Cit-Aib-Asn-Cys]-Tle-Thr-Cmp-lys(DOTA)-NH₂ (PSM-0207);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-NHnPen (PSM-0208);
 DOTA-Bal-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0209);
 Ac-Thr-Aib-Phe-[Cys-Gln-Arg-Aib-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0210);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Lys(DOTA-Pab)-Asn-Cys]-Tle-Thr-NH₂ (PSM-0211);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Asp-Ttds-lys(DOTA)-NH₂ (PSM-0212);
 SaPr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Cmp-lys(DOTA)-NH₂ (PSM-0215);
 DOTA-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Bal-NH₂ (PSM-0216);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Dfp-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0217);
 DOTAGA-Cmp-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0218);
 DOTA-Cmp-Leu-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0220);

DOTA-Pamb-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-en (PSM-0221);
 DOTA-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-en (PSM-0222);
 DOTA-Cmp-Aib-Pcf-[Cys-Lys-Arg(Ac)-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0223);
 SaPr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0224);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Har-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0225);
 H-Met-Thr-Ala-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Leu-Thr-Asp-Gly-Ser-Ttds-Ttds-Ttds-Lys(Bio)-NH₂ (PSM-0226);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys-Arg-amd-Asn-Cys]-Tle-Thr-NH₂ (PSM-0227);
 Ac-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0228);
 Ac-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Met-Cys]-Tle-Thr-NH₂ (PSM-0229);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-NH₂ (PSM-0230);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Tle-Thr-Ttds-lys(DOTA)-NH₂ (PSM-0231);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Nmg-Asn-Cys]-Tle-Thr-NH₂ (PSM-0232);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Pam-Asn-Cys]-Tle-Thr-NH₂ (PSM-0233);
 DOTA-Ttds-Thr-Aib-Phe-[Cys-Lys-Cit-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0234);
 Ac-Thr-Aib-Phe-[Cys-Lys-Nmr-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0235);
 Ac-Thr-Aib-Pcf-[Cys-Nle-Gln(Gu)-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0236);
 DOTA-Ttds-Thr-Aib-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Tle-Thr-NH₂ (PSM-0237);
 Ac-Thr-Aib-Pcf-[Cys-Lys-Cit-Aib-Trp-Cys]-Tle-Thr-NH₂ (PSM-0238);
 Hex-Thr-Aib-Pcf-[Cys-Lys-Cit-Aib-Asn-Cys]-Tle-Thr-lys(DOTA-Cmp)-NH₂ (PSM-0239);
 Ac-Thr-Aib-Pcf-[Cys-Lys-Cit-Aib-Arg-Cys]-Tle-Thr-NH₂ (PSM-0240);
 DOTA-Cmp-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-en (PSM-0241);
 Ac-Thr-Aib-Mcf-[Cys-Lys-Arg-Lys(DOTA-O₂Oc)-Asn-Cys]-Tle-Thr-NH₂ (PSM-0243);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Kip-Arg(Me)-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0244);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys-Orn-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0245);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys(Me)-Arg(Me)-ala-Asn-Cys]-Tle-Thr-NH₂ (PSM-0246);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys(Me)-RMe₂-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0247);

DOTA-Cmp-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0248);
 Ac-Thr-Aib-1Ni-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0249);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Ttds-Ttds-Lys(Bio)-NH₂ (PSM-0250);
 DOTA-Ttds-Thr-Ala-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Leu-Thr-Asp-NH₂ (PSM-0251);
 Ac-Thr-Aib-Phe-[Cys-Lys-Cit-Aib-Asn-Cys]-Tle-Thr-Cmp-lys(DOTA)-NH₂ (PSM-0252);
 Ac-Thr-Aib-Phe-[Cys-Lys-Glu-Aib-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0253);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys(Me)-Eew-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0254);
 DOTA-Cmp-Thr-Aib-Mpa-[Cys-Lys-Cit-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0255);
 DOTA-Cmp-Thr-ams-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0256);
 DOTA-Cmp-Thr-Aib-Opa-[Cys-Lys(Me)-Arg(Me)-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0257);
 nBuCAyl-Thr-Aib-Phe-[Cys-Lys-Opy-Aib-Asn-Cys]-Tle-Thr-Cmp-lys(DOTA)-NH₂ (PSM-0258);
 DOTA-Ttds-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0259);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys-Arg-glu-Asn-Cys]-Tle-Thr-NH₂ (PSM-0260);
 DOTA-APAc-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0261);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Glu-NH₂ (PSM-0262);
 DOTA-APAc-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0263);
 Ac-Thr-Aib-Mtf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0264);
 Ac-Thr-Ala-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Tle-Thr-Asp-Ttds-lys(DOTA)-NH₂ (PSM-0266);
 HPA-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-lys(DOTA)-NH₂ (PSM-0267);
 Ac-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-en-DOTA (PSM-0269);
 DOTA-Pamb-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0270);
 AF488Ahx-Ttds-Ttds-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0272);
 DOTA-Pamb-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-en (PSM-0273);
 DOTA-Cmp-Thr-Aib-Eaa-[Cys-Lys-Cit-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0274);
 Ac-Thr-Aib-Mcf-[Cys-Lys-Cit-Aib-Asn-Cys]-Tle-Thr-Cmp-lys(DOTA)-NH₂ (PSM-0275);
 Ac-Thr-Aib-Pnf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0278);

Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Ser-Cys]-Tle-Thr-NH₂ (PSM-0279);
 Ac-Thr-Aib-Phe-[Cys-Lys-Cit-Aib-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0280);
 Ac-Aib-Pcf-[Cys-Lys-Arg-Lys(DOTA-APAc)-Asn-Cys]-Tle-Thr-NH₂ (PSM-0282);
 DOTA-Pamb-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0283);
 Ac-Thr-Aib-Mcf-[Cys-Lys-Cit-Lys(DOTA-O₂Oc)-Asn-Cys]-Tle-Thr-NH₂ (PSM-0284);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Ttds-lys(DOTA)-NH₂ (PSM-0285);
 Ac-Thr-Ala-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Nle-Thr-Asp-NH₂ (PSM-0287);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-lys(DOTA)-NH₂ (PSM-0288);
 Hex-Thr-Aib-Phe-[Cys-Lys-Gln-Aib-Asn-Cys]-Tle-Thr-Ttds-lys(DOTA)-NH₂ (PSM-0289);
 Iva-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-lys(DOTA)-NH₂ (PSM-0292);
 Ac-Thr-Aib-Pcf-[Cys-Lys-Cit-Aib-Ser-Cys]-Tle-Thr-NH₂ (PSM-0293);
 Ac-Thr-Aib-Pff-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0294);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Tle-Thr-Asp-Ttds-lys(DOTA)-NH₂ (PSM-0295);
 DOTA-Cmp-Thr-Aib-Mpa-[Cys-Lys(Me)-Arg(Me)-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0296);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Gab-NH₂ (PSM-0297);
 Ac-Aib-Pcf-[Cys-Lys-Arg(Ac)-Aib-Asn-Cys]-Tle-Thr-Cmp-lys(DOTA)-NH₂ (PSM-0298);
 Ac-Ala-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Leu-Thr-Asp-Ttds-lys(DOTA)-NH₂ (PSM-0299);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-OH (PSM-0300);
 Ac-Thr-Aib-Mcf-[Cys-Lys-Arg-Lys(DOTAGA-O₂Oc)-Asn-Cys]-Tle-Thr-NH₂ (PSM-0301);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys-Arg-Amd-Asn-Cys]-Tle-Thr-NH₂ (PSM-0302);
 Ac-Thr-Aib-Phe-[Cys-Lys-Gln-Aib-Asn-Cys]-Tle-Thr-Ttds-lys(DOTA)-NH₂ (PSM-0303);
 DOTA-Cmp-Thr-Aib-6Clw-[Cys-Lys-Cit-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0304);
 DOTA-Ttds-Thr-Ala-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Leu-Thr-NH₂ (PSM-0305);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-en(Me)₂ (PSM-0306);
 Ac-Thr-Aib-Phe-[Cys-Lys-Cit-Ala-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0307);
 DOTA-Cmp-Thr-Aib-5Clw-[Cys-Lys(Me)-Arg(Me)-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0308);
 DOTA-Ahx-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0310);

Ac-Thr-Ala-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Nle-Thr-Gab-OH (PSM-0313);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys-Arg-ams-Asn-Cys]-Tle-Thr-NH₂ (PSM-0314);
 Ac-Thr-Aib-Phe-[Cys-Lys-arg-Ala-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0315);
 DOTA-Pab-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0316);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys-Har-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0317);
 Ac-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0318);
 Ac-Thr-Ala-Nmf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0319);
 Ac-Aib-Pcf-[Cys-Lys-Arg(Me)-Aib-Asn-Cys]-Tle-en-DOTA (PSM-0320);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Apc(DOTA)-Asn-Cys]-Tle-Thr-NH₂ (PSM-0321);
 Ac-Thr-Aib-Pcf-[Cys-Lys-Cit-Aib-Asn-Cys]-Tle-Thr-lys(DOTA-Cmp)-NH₂ (PSM-0322);
 HPA-Aib-Pcf-[Cys-Lys-Arg-Lys(DOTA-APAc)-Asn-Cys]-Tle-Thr-NH₂ (PSM-0324);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Lys(DOTA)-Asn-Cys]-Tle-Thr-NH₂ (PSM-0326);
 SaPr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-lys(DOTA)-NH₂ (PSM-0328);
 Ac-Thr-Aib-Pcf-[Cys-Lys-Cit-Aib-Asn-Cys]-Tle-Thr-Cmp-lys(DOTA)-NH₂ (PSM-0329);
 Ac-Thr-Ala-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Leu-Thr-Asp-Ttds-lys(DOTA)-NH₂ (PSM-0330);
 DOTA-Cmp-Thr-Aib-Pcf-[Smc-Lys-Arg-Aib-Asn-Cys]-Tle-NH₂ (alternative: DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Smc]-Tle-NH₂) (PSM-0332);
 Ac-Thr-Aib-Phe-[Cys-Lys-Gln-Aib-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0334);
 Ac-Thr-Ala-Phe-[Cys-Lys-Arg-Ala-Ala-Cys]-Nle-Thr-Asp-NH₂ (PSM-0335);
 Ac-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0336);
 Ac-Thr-Aib-Pcf-[Cys-Lys-Nle-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0338);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Cmp-lys(DOTAGA)-NH₂ (PSM-0339);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys-Nmr-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0340);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys-Lys(Ac)-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0341);
 DOTA-Ttds-Thr-Ala-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0342);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys-Arg(Me)-Aib-Asn-Cys]-Tle-NH₂ (PSM-0345);
 DOTA-Cmp-Thr-Amd-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0346);

Ac-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Cmp-lys(DOTA)-NH₂ (PSM-0349);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Ile-Thr-NH₂ (PSM-0350);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys-Arg(Me)-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0351);
 DOTA-Bal-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0352);
 Iva-Aib-Pcf-[Cys-Lys-Arg-Lys(DOTA-APAc)-Asn-Cys]-Tle-Thr-NH₂ (PSM-0353);
 DOTA-Cmp-Thr-Aib-Mcf-[Cys-Lys(Me)-Arg(Me)-Aib-Asn-Cys]-Tle-NH₂ (PSM-0354);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys(Me)-RMe₃-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0355);
 DOTA-Cmp-Ile-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0357);
 DOTA-Cmp-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-NH₂ (PSM-0361);
 Ac-Thr-Aib-Phe-[Cys-Lys-Glu-Ala-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0363);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys-Cit-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0365);
 DOTA-Cmp-Thr-amd-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0366);
 Ac-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-NH₂ (PSM-0367);
 DOTA-Ahx-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0368);
 DOTA-Cmp-Thr-Ams-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0369);
 Ac-Thr-Aib-Pcf-[Cys-Lys-Arg-Lys(DOTA-O₂Oc)-Asn-Cys]-Tle-Thr-NH₂ (PSM-0370);
 nBuCAyl-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Cmp-lys(DOTA)-NH₂ (PSM-0371);
 Ac-Thr-Aib-Pmf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0372);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0374);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Deg-Asn-Cys]-Tle-Thr-NH₂ (PSM-0375);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Trp-NH₂ (PSM-0376);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Val-Nmt-NH₂ (PSM-0377);
 H-Cmp-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Cmp-lys(DOTA)-NH₂ (PSM-0378);
 Ac-Cmp-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-en-DOTA (PSM-0379);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys(Me)-Arg(Me)-Aib-Asn-Cys]-Tle-NH₂ (PSM-0380);
 DOTA-Pamb-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-NH₂ (PSM-0381);

DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys-Arg-Ams-Asn-Cys]-Tle-Thr-NH₂ (PSM-0382);
 Ac-Thr-Aib-Mcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0383);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-en (PSM-0384);
 Ac-Thr-Aib-Phe-[Cys-Lys-Gln-Lys(DOTA)-Asn-Cys]-Tle-Thr-NH₂ (PSM-0385);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Pro-NH₂ (PSM-0388);
 Ac-Thr-Ala-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Nle-Thr-asp-NH₂ (PSM-0389);
 DOTA-Cmp-Thr-Aib-6Clw-[Cys-Lys(Me)-Arg(Me)-Aib-Asn-Cys]-Tle-NH₂ (PSM-0390);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Ape-DOTA (PSM-0391);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-4Tfp-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0392);
 Ac-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-en (PSM-0393);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Aib-Thr-NH₂ (PSM-0394);
 DOTA-Cmp-Thr-Aib-Pff-[Cys-Lys(Me)-Arg(Me)-Aib-Asn-Cys]-Tle-NH₂ (PSM-0395);
 DOTA-Cmp-Thr-Aib-Mtf-[Cys-Lys(Me)-Arg(Me)-Aib-Asn-Cys]-Tle-NH₂ (PSM-0396);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Lys(DOTA)-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0397);
 DOTA-Ttds-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0398);
 Hex-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-lys(DOTA-Cmp)-NH₂ (PSM-0400);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Lys(DOTA-O₂Oc)-Asn-Cys]-Tle-Thr-NH₂ (PSM-0401);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-asn-Cys]-Tle-Thr-NH₂ (PSM-0402);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Oic-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0403);
 Ac-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-lys(DOTA)-NH₂ (PSM-0404);
 Hex-Thr-Ala-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Leu-Thr-Asp-Ttds-lys(DOTA)-NH₂ (PSM-0405);
 DOTA-Cmp-Thr-Ams-Pcf-[Cys-Lys-Arg-Ams-Asn-Cys]-Tle-Thr-NH₂ (PSM-0407);
 Ac-Thr-Nmg-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0408);
 DOTA-Cmp-Thr-Aib-Opa-[Cys-Lys(Me)-Arg(Me)-Aib-Asn-Cys]-Tle-NH₂ (PSM-0409);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys(Me)-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0410);
 Ac-Thr-Aib-Hfe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0411);
 Ac-Thr-Aib-Mmf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0412);

DOTA-PPAc-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0413);
 Ac-Thr-Ala-Amf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0414);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Lys(DOTA-Cmp)-Asn-Cys]-Tle-Thr-NH₂ (PSM-0415);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys-Arg-Glu-Asn-Cys]-Tle-Thr-NH₂ (PSM-0416);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Lys(DOTA-Pamb)-Asn-Cys]-Tle-Thr-NH₂ (PSM-0419);
 DOTA-Cmp-Thr-Aib-Pcf-[Smc-Lys(Me)-Arg(Me)-Aib-Asn-Cys]-Tle-NH₂ (alternative: DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys(Me)-Arg(Me)-Aib-Asn-Smc]-Tle-NH₂) (PSM-0420);
 Ac-Thr-Aib-Pcf-[Cys-Lys-Cit-Aib-Asn-Cys]-Ileu-Thr-NH₂ (PSM-0421);
 Ac-Thr-Aib-Phe-[Cys-Tap-Arg-Ala-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0422);
 Ac-Thr-Aib-Phe-[Cys-Lys-Gln-Lys(DOTA-Ttds)-Asn-Cys]-Tle-Thr-NH₂ (PSM-0423);
 Ac-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-NH₂ (PSM-0424);
 Hex-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Asp-Ttds-lys(DOTA)-NH₂ (PSM-0425);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Bal-NH₂ (PSM-0426);
 nBuCAyl-Thr-Aib-Pcf-[Cys-Lys-Opy-Aib-Asn-Cys]-Tle-Thr-Cmp-lys(DOTA)-NH₂ (PSM-0427);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Cmp-lys(DOTA)-NH₂ (PSM-0428);
 DOTA-Cmp-Thr-Aib-Mcf-[Cys-Lys-Cit-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0431);
 DOTA-Pamb-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Bal-NH₂ (PSM-0432);
 nBuCAyl-Thr-Aib-Phe-[Cys-Lys-Cit-Aib-Asn-Cys]-Tle-Thr-Cmp-lys(DOTA)-NH₂ (PSM-0434);
 Ac-Thr-Aib-Phe-[Cys-Gln-Arg-Ala-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0435);
 DOTA-Bal-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0437);
 Ac-Thr-Aib-Phe-[Cys-Aph-Arg-Ala-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0439);
 Ac-Thr-Aib-Cys(Bzl)-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0441);
 Ac-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0442);
 Ac-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-NH₂ (PSM-0443);
 Iva-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-lys(DOTA)-NH₂ (PSM-0444);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0445);
 DOTA-Pab-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0448);

DOTA-Cmp-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Bal-NH₂ (PSM-0449);
 Iva-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0450);
 Ac-Thr-Aib-Phe-[Cys-Nmk-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0451);
 nBuCAyl-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-lys(DOTA-Cmp)-NH₂ (PSM-0452);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Leu-NH₂ (PSM-0453);
 DOTA-Cmp-Thr-Aib-Ppa-[Cys-Lys-Cit-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0454);
 DOTA-Cmp-Nmt-Ala-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0455);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-en(Me) (PSM-0456);
 DOTA-Pamb-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-NH₂ (PSM-0458);
 DOTA-Cmp-Thr-Aib-Mnf-[Cys-Lys(Me)-Arg(Me)-Aib-Asn-Cys]-Tle-NH₂ (PSM-0459);
 Ac-Thr-Ala-Phe-[Cys-Lys-Arg-Pro-Asn-Cys]-Nle-Thr-Asp-NH₂ (PSM-0460);
 Hib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0461);
 Hex-Thr-Aib-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Tle-Thr-Ttds-lys(DOTA)-NH₂ (PSM-0462);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Lys(DOTA-APAc)-Asn-Cys]-Tle-Thr-NH₂ (PSM-0464);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Lys(DOTA-Ttds)-Asn-Cys]-Tle-Thr-NH₂ (PSM-0465);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys(Ac)-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0466);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Bal-NH₂ (PSM-0467);
 Ac-Ser-Ala-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Nle-Thr-Asp-NH₂ (PSM-0469);
 nBuCAyl-Thr-Aib-Mcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Cmp-lys(DOTA)-NH₂ (PSM-0470);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Pab-lys(DOTA)-NH₂ (PSM-0471);
 Ac-Aib-Pcf-[Cys-Lys(Me)-Arg-Aib-Asn-Cys]-Tle-en-DOTA (PSM-0472);
 Ac-Thr-Ala-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Nle-Ala-Asp-NH₂ (PSM-0476);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Gly-NH₂ (PSM-0477);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asp-Cys]-Tle-Thr-NH₂ (PSM-0478);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Gly-Cys]-Tle-Thr-NH₂ (PSM-0479);
 DOTA-Ttds-Thr-Ala-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Leu-NH₂ (PSM-0480);

Ac-Aib-Pcf-[Cys-Lys(Me)-Arg(Me)-Aib-Asn-Cys]-Tle-en-DOTA (PSM-0481);

Ac-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Cmp-lys(DOTA)-NH₂ (PSM-0482);

DOTA-Cmp-Thr-Aib-Pcf-[Cys-KMe₃-Arg(Me)-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0483);

nBuCAyl-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Cmp-lys(DOTA)-NH₂ (PSM-0484);

DOTA-Cmp-Thr-Aib-Pcf-[Cys-Hgn-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0485);

Ac-Thr-Aib-Mcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Cmp-lys(DOTA)-NH₂ (PSM-0486);

Ac-Thr-Aib-Tyr-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0488);

DOTA-Cmp-Aib-Pcf-[Cys-Lys-Gln(Gu)-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0489);

DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys(Bio)-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0490);

Ac-Ala-Ala-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Nle-Thr-Asp-NH₂ (PSM-0491);

Ac-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-OH (PSM-0493);

Ac-Aib-Pcf-[Cys-Lys-Gln(Gu)-Aib-Asn-Cys]-Tle-Thr-Cmp-lys(DOTA)-NH₂ (PSM-0494);

Crown-Cmp-Thr-Aib-Pcf-[Cys-Lys(Me)-Arg(Me)-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0495);

Ac-Thr-Aib-Pcf-[Cys-Lys-Cit-Aib-Glu-Cys]-Tle-Thr-NH₂ (PSM-0496);

DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Nml-Thr-NH₂ (PSM-0497);

H-Met-Thr-Ala-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Leu-Thr-Asp-Gly-Ser-NH₂ (PSM-0498);

DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys(Me)-Egd-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0499);

nBuCAyl-Thr-Aib-Pcf-[Cys-Lys-Cit-Aib-Asn-Cys]-Tle-Thr-lys(DOTA-Cmp)-NH₂ (PSM-0500);

Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Nle-Thr-Asp-NH₂ (PSM-0501);

Hex-Thr-Aib-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Tle-Thr-Asp-Ttds-lys(DOTA)-NH₂ (PSM-0502);

DOTA-Cmp-Thr-Aib-Mmf-[Cys-Lys(Me)-Arg(Me)-Aib-Asn-Cys]-Tle-NH₂ (PSM-0503);

DOTA-Ttds-Thr-Ala-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Nle-Thr-Asp-NH₂ (PSM-0504);

DOTA-O₂Oc-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0505);

Ac-Aib-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0506);

DOTA-Cmp-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0507);

Ac-Thr-Pam-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0508);

HPA-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Cmp-lys(DOTA)-NH₂ (PSM-0509);
Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-NHBu (PSM-0510);
DOTA-Cmp-Thr-Aib-Pcf-[Cys-Orn-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0511);
DOTA-Cmp-Thr-Aib-Opa-[Cys-Lys-Cit-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0512);
DOTA-Ahx-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0513);
Ac-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Bal-NH₂ (PSM-0514);
Macropa-Cmp-Thr-Aib-Pcf-[Cys-Lys(Me)-Arg(Me)-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0515);
Ac-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-en-DOTA (PSM-0516);
Ac-Thr-Aib-2Ni-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0517);
HYDAc-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0518);
DOTA-Ttds-Thr-Aib-Phe-[Cys-Lys-Gln-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0521);
Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Pamb-lys(DOTA)-NH₂ (PSM-0522);
Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-O₂Oc-lys(DOTA)-NH₂ (PSM-0529);
HPA-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0530);
DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys-Hgn-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0531);
Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Dtc-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0532);
Ac-Thr-Ala-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Nle-Thr-Asp-Ttds-lys(DOTA)-NH₂ (PSM-0533);
DOTA-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-NH₂ (PSM-0534);
Ac-Thr-Aib-Phe-[Cys-lys-Arg-Ala-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0535);
DOTA-Cmp-Tle-Aib-Pcf-[Cys-Lys(Me)-Arg(Me)-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0538);
DOTA-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Bal-NH₂ (PSM-0539);
Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Gln-NH₂ (PSM-0540);
Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Phe-Cys]-Tle-Thr-NH₂ (PSM-0541);
Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Lys(DOTA-Ttds)-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0542);
DOTA-APAc-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0543);
Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Leu-Cys]-Tle-Thr-NH₂ (PSM-0545);
DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys-Urr-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0546);

Ac-Thr-Pro-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Nle-Thr-Asp-NH₂ (PSM-0547);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Nmk-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0548);
 DOTA-Cmp-Thr-Aib-Ptf-[Cys-Lys(Me)-Arg(Me)-Aib-Asn-Cys]-Tle-NH₂ (PSM-0549);
 Ac-Thr-Aib-Ptf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0550);
 Ac-Thr-Aib-Mff-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0551);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Tle-Thr-NH₂ (PSM-0552);
 DOTA-Cmp-Thr-Aib-Mff-[Cys-Lys(Me)-Arg(Me)-Aib-Asn-Cys]-Tle-NH₂ (PSM-0553);
 Ac-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-OH (PSM-0554);
 Ac-Thr-Aib-Mnf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0555);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Phe-NH₂ (PSM-0556);
 Ac-Thr-Aib-Ocf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0558);
 Ac-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0559);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Npg-NH₂ (PSM-0560);
 Ac-Thr-Ala-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Nle-Thr-Ala-NH₂ (PSM-0562);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Glu-Cys]-Tle-Thr-NH₂ (PSM-0563);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0565);
 Ac-Thr-Aib-Phe-[Smc-Lys-Arg-Ala-Asn-Cys]-Tle-Thr-Asp-NH₂ (alternative: Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Ala-Asn-Smc]-Tle-Thr-Asp-NH₂) (PSM-0567);
 Hex-Thr-Ala-Phe-[Cys-Lys-Arg-Ala-Asn-Cys]-Tle-Thr-Asp-Ttds-lys(DOTA)-NH₂ (PSM-0568);
 Ac-Thr-Aib-Pcf-[Cys-Lys-Arg(Ac)-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0569);
 Ac-Thr-Aib-Pcf-[Cys-Nle-Arg(Ac)-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0570);
 nBuCAyl-Thr-Aib-Mcf-[Cys-Lys-Opy-Aib-Asn-Cys]-Tle-Thr-Cmp-lys(DOTA)-NH₂ (PSM-0571);
 DOTA-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0573);
 DOTA-Pamb-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Bal-NH₂ (PSM-0574);
 Bio-Ttds-Ttds-Thr-Aib-Pcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0575);
 Hex-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Ttds-lys(DOTA)-NH₂ (PSM-0576);
 HO-Succinyl-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0577);

Ac-Thr-Ala-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Nle-Thr-Asp-NH₂ (PSM-0578);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys-Arg(EtCAyl)-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0579);
 DOTA-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0580);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Lys(DOTA-Ahx)-Asn-Cys]-Tle-Thr-NH₂ (PSM-0582);
 DOTA-Cmp-Thr-Aib-Mcf-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0583);
 Ac-Thr-Aib-Pcf-[Cys-Lys-Cit-Aib-Leu-Cys]-Tle-Thr-NH₂ (PSM-0584);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys-Arg-Ala-Nmn-Cys]-Tle-Thr-NH₂ (PSM-0585);
 Ac-Thr-Aib-Trp-[Cys-Lys-Arg-Aib-Asn-Cys]-Tle-Thr-Asp-NH₂ (PSM-0587);
 Ac-Thr-Aib-Phe-[Cys-Lys-Arg-Aib-Trp-Cys]-Tle-Thr-NH₂ (PSM-0589);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys(Me)-RMe2a-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0590);
 Macropa-Cmp-Thr-Aib-Pcf-[Cys-Lys(Me)-Arg(Me)-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0591);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys(Me)-RMe1-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0592);
 DOTAM-Cmp-Thr-Aib-Pcf-[Cys-Lys(Me)-Arg(Me)-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0593);
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys(Me)-Arg(Me)-Aib-Asn-Cys]-OH (PSM-0594);
 LSC-Cmp-Thr-Aib-Pcf-[Cys-Lys(Me)-Arg(Me)-Aib-Asn-Cys]-Tle-Thr-NH₂ (PSM-0601);
 DOTA-Cmp-Thr-Aib-Phe-[Cys-Lys(Me)-Arg(Me)-Aib-Asn-Cys]-Tle-en-H (PSM-0605) and
 DOTA-Cmp-Thr-Aib-Pcf-[Cys-Lys(Me)-Arg(Me)-Aib-Asn-Cys]-Tle-Bal-NH₂(PSM-0606).

33. The compound of any one of claims 1 to 32, or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein the compound comprises a diagnostically active nuclide or a therapeutically active nuclide.

34. The compound of claim 33, or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein the compound comprises a diagnostically active nuclide; preferably diagnostically active nuclide is a diagnostically active radionuclide, more preferably the diagnostically active radionuclide is selected from the group consisting of ⁴³Sc, ⁴⁴Sc, ⁵¹Mn, ⁵²Mn, ⁶⁴Cu, ⁶⁷Ga, ⁶⁸Ga, ⁸⁶Y, ⁸⁹Zr, ^{94m}Tc, ^{99m}Tc, ¹¹¹In, ¹⁵²Tb, ¹⁵⁵Tb, ¹⁷⁷Lu, ²⁰¹Tl, ²⁰³Pb, ¹⁸F, ⁷⁶Br, ⁷⁷Br, ¹²³I, ¹²⁴I, and ¹²⁵I.

35. The compound of any one of claims 1 to 33, or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein the compound comprises a therapeutically active nuclide; preferably the therapeutically active nuclide is a therapeutically active radionuclide; more preferably the therapeutically active radionuclide is selected from the group consisting of ^{47}Sc , ^{67}Cu , ^{89}Sr , ^{90}Y , ^{111}In , ^{153}Sm , ^{149}Tb , ^{161}Tb , ^{177}Lu , ^{186}Re , ^{188}Re , ^{212}Pb , ^{212}Bi , ^{213}Bi , ^{223}Ra , ^{224}Ra , ^{225}Ac , ^{226}Th , ^{227}Th , ^{131}I , and ^{211}At .

36. A compound or pharmaceutically acceptable salt, solvate or hydrate thereof of any one of claims 1 to 34, for use in a method for the diagnosis of a disease, preferably the method for diagnosis is an imaging method.

37. A compound or pharmaceutically acceptable salt, solvate or hydrate thereof of any one of claims 1 to 33 and 35, for use in a method for the treatment of a disease.

38. Use of a compound or pharmaceutically acceptable salt, solvate or hydrate thereof of any one of claims 1 to 33 and 35 in the manufacture of a medicament for the treatment of a disease.

39. The use according to any one of claims 36 to 38, wherein the disease involves cells showing upregulated expression of prostate specific membrane antigen (PSMA), preferably diseased tissue containing cells showing upregulated expression of PSMA and/or

wherein the disease is a neoplasm, preferably a cancer or tumor; more preferably the tumor is selected from the group comprising an advanced tumor, a metastatic tumor, and a primary tumor; and most preferably the tumor is selected

a) from the group comprising a prostate tumor, a metastasized prostate tumor, a lung tumor, a renal tumor, a glioblastoma, a pancreatic tumor, a bladder tumor, a sarcoma, a melanoma, a breast tumor, a colon tumor, a pheochromocytoma, an esophageal tumor, a stomach tumor, a carcinoma, a squamous carcinoma (e.g., cervical canal, eyelid, tunica conjunctiva, vagina, lung, oral cavity, skin, urinary bladder, tongue, larynx, and gullet), and an adenocarcinoma (e.g., prostate, small intestine, endometrium, cervical canal, large intestine, lung, pancreas, gullet, rectum, uterus, stomach, mammary gland, and ovary), and combinations thereof, or

b) from the group comprising: prostate cancer (e.g., metastatic castration resistant prostate cancer), renal cancer (e.g., clear cell carcinoma), head cancer, neck cancer, head and neck cancer,

lung cancer (e.g., non-small cell lung cancer), salivary gland cancer, breast cancer, colorectal cancer, esophageal cancer, stomach cancer, liver cancer (e.g., hepatocellular cancer), thyroid cancer, glioblastoma, glioma, gall bladder cancer, laryngeal cancer, leukemia/lymphoma, uterine cancer, skin cancer (e.g., melanoma), endocrine cancer, sarcoma, urinary cancer, pancreatic cancer, gastrointestinal cancer, ovarian cancer, cervical cancer, endometrial cancer, fallopian tube cancer, primary peritoneal cancer, hematological cancer (e.g., diffuse large B cell lymphoma, Hodgkin's lymphoma, Non-Hodgkin's lymphoma, follicular lymphoma, acute myeloid leukemia, or multiple myeloma), cancer of unknown primary, adenomas, and tumor neovasculature.

40. The use according to any one of claims 1 to 34, for use in a method for the identification of a subject, wherein the subject is likely to respond or likely not to respond to a treatment of a disease, wherein the method for the identification of a subject comprises carrying out a method of diagnosis using the compound or pharmaceutically acceptable salt, solvate or hydrate thereof of any one of claims 1 to 34, preferably a method for the diagnosis of a disease as described in any one of claims 36 and 39,

for use in a method for the selection of a subject from a group of subjects, wherein the subject is likely to respond or likely not to respond to a treatment of a disease, wherein the method for the selection of a subject from a group of subjects comprises carrying out a method of diagnosis using the compound or pharmaceutically acceptable salt, solvate or hydrate thereof of any one of claims 1 to 34, preferably a method for the diagnosis of a disease as described in any one of claims 36 and 39,

for use in a method for the stratification of a group of subjects into subjects which are likely to respond to a treatment of a disease, and into subjects which are not likely to respond to a treatment of a disease, wherein the method for the stratification of a group of subjects comprises carrying out a method of diagnosis using the compound or pharmaceutically acceptable salt, solvate or hydrate thereof of any one of claims 1 to 34, preferably a method for the diagnosis of a disease as described in any one of claims 36 and 39.

41. The use according to claim 40, wherein the disease is a disease involving the prostate specific membrane antigen (PSMA) protein, or wherein the disease involves cells showing upregulated expression of prostate specific membrane antigen (PSMA); preferably the tumor is selected from the group comprising a prostate tumor, a metastasized prostate tumor, a lung tumor, a renal tumor, a glioblastoma, a pancreatic tumor, a bladder tumor, a sarcoma, a melanoma, a breast tumor, a colon tumor, a pheochromocytoma, an esophageal tumor, a stomach tumor, a carcinoma, a squamous carcinoma (e.g., cervical canal, eyelid, tunica conjunctiva, vagina, lung, oral cavity, skin, urinary bladder, tongue, larynx, and gullet), and an adenocarcinoma (e.g., prostate, small

intestine, endometrium, cervical canal, large intestine, lung, pancreas, gullet, rectum, uterus, stomach, mammary gland, and ovary), and combinations thereof.

42. The use according to claims 1 to 34, for use in a method for delivering a diagnostically active radionuclide or a therapeutically active radionuclide to prostate specific membrane antigen (PSMA); preferably the diagnostically active radionuclide is selected from the group consisting of ^{43}Sc , ^{44}Sc , ^{51}Mn , ^{52}Mn , ^{64}Cu , ^{67}Ga , ^{68}Ga , ^{86}Y , ^{89}Zr , $^{94\text{m}}\text{Tc}$, $^{99\text{m}}\text{Tc}$, ^{111}In , ^{152}Tb , ^{155}Tb , ^{177}Lu , ^{201}Tl , ^{203}Pb , ^{18}F , ^{76}Br , ^{77}Br , ^{123}I , ^{124}I , and ^{125}I , preferably ^{18}F , ^{43}Sc , ^{44}Sc , ^{64}Cu , ^{67}Ga , ^{68}Ga , ^{86}Y , ^{89}Zr , $^{99\text{m}}\text{Tc}$, ^{111}In , ^{152}Tb , ^{155}Tb , and ^{203}Pb , and more preferably ^{18}F , ^{64}Cu , ^{68}Ga , and ^{111}In , and the therapeutically active radionuclide is selected from the group consisting of ^{47}Sc , ^{67}Cu , ^{89}Sr , ^{90}Y , ^{111}In , ^{153}Sm , ^{149}Tb , ^{161}Tb , ^{177}Lu , ^{186}Re , ^{188}Re , ^{212}Pb , ^{212}Bi , ^{213}Bi , ^{223}Ra , ^{224}Ra , ^{225}Ac , ^{226}Th , ^{227}Th , ^{131}I , ^{211}At , preferably ^{47}Sc , ^{67}Cu , ^{90}Y , ^{161}Tb , ^{177}Lu , ^{188}Re , ^{212}Pb , ^{212}Bi , ^{213}Bi , ^{225}Ac , ^{227}Th , and more preferably ^{90}Y , ^{161}Tb , ^{177}Lu , ^{212}Pb , ^{225}Ac , and ^{227}Th ,

preferably the prostate specific membrane antigen (PSMA) is expressed by a cell, preferably a prostate cell, a metastasized prostate cell, a lung cell, a renal cell, a pancreatic cell, a bladder cell, a breast cell, a colon cell, a germ cell, an esophageal cell, a stomach cell, an endothelial cell and combinations thereof each showing upregulated expression of PSMA.

43. A composition, preferably a pharmaceutical composition, wherein the composition comprises a compound or pharmaceutically acceptable salt, solvate or hydrate thereof according to any one of claims 33 and 35, and a pharmaceutically acceptable excipient.

44. A kit comprising a compound or pharmaceutically acceptable salt, solvate or hydrate thereof according to any one of claims 1 to 35, one or more optional excipient(s) and optionally one or more device(s), whereby the device(s) is/are selected from the group comprising a labeling device, a purification device, a handling device, a radioprotection device, an analytical device or an administration device, preferably the kit is for use in any method as defined in any of the preceding claims.